Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Abstract 3221: Targeting ARID1A-mutated gastric cancer cells with synthetic lethal approaches

Menghan Fang, Youfen Lin, Chaorong Xue, Kaiqin Sheng, Zegeng Guo, Yuting Han, Hanbin Lin, Yuecheng Wu, Stephen B. Howell, Xu Lin, Xinjian Lin

Cancer Res (2024) 84 (6_Supplement): 3221.

https://doi.org/10.1158/1538-7445.AM2024-3221

Published: 22 March 2024

View article titled, Abstract 3221: Targeting ARID1A-mutated gastric cancer cells with synthetic lethal approaches

Journal Articles

Abstract 3901: Therapeutic targeting of LGR5-positive cancer stem cells

Maria Carmen Mulero, Catherine Rice, Sukshala A. Jahdav, Willie Pi, Alexander Lin, Mindy Nguyen, Owen Tai, Stephen B. Howell

Cancer Res (2024) 84 (6_Supplement): 3901.

https://doi.org/10.1158/1538-7445.AM2024-3901

Published: 22 March 2024

View article titled, Abstract 3901: Therapeutic targeting of LGR5-positive cancer stem cells

Journal Articles

Abstract 4411: A gene set enrichment analysis approach in single-cells along pseudotime trajectories reveals the dynamic activity of oncogenic pathways

Alexander T. Wenzel, Devora Champa, Stephen B. Howell, Jill P. Mesirov, Olivier Harismendy

Cancer Res (2020) 80 (16_Supplement): 4411.

https://doi.org/10.1158/1538-7445.AM2020-4411

Published: 15 August 2020

View article titled, Abstract 4411: A gene set enrichment analysis approach in single-cells along pseudotime trajectories reveals the dynamic activity of oncogenic pathways

Journal Articles

Abstract 1323: CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients

Hongying Zhang, Andrea Local, Jeffrey W. Tyner, Stephen E. Kurtz, Beth Wilmot, Shannon Mcweeney, Brian J. Druker, Stephen B. Howell, William G. Rice

Cancer Res (2019) 79 (13_Supplement): 1323.

https://doi.org/10.1158/1538-7445.AM2019-1323

Published: 01 July 2019

View article titled, Abstract 1323: CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients

Journal Articles

Abstract 2096: Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in malignant B cells

Andrea Local, Cheng-Yu Tsai, Hongying Zhang, Susan Sheng, Khalid Benbatoul, Stephen B. Howell, William G. Rice

Cancer Res (2019) 79 (13_Supplement): 2096.

https://doi.org/10.1158/1538-7445.AM2019-2096

Published: 01 July 2019

View article titled, Abstract 2096: Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in malignant B cells

Journal Articles

Abstract 794: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro

Hongying Zhang, Andrea Local, Khalid Benbatoul, Peter Folger, Susan Sheng, Cheng-Yu Tsai, Stephen B. Howell, William G. Rice

Cancer Res (2018) 78 (13_Supplement): 794.

https://doi.org/10.1158/1538-7445.AM2018-794

Published: 01 July 2018

View article titled, Abstract 794: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro

Journal Articles

Abstract 4840: APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency

Cheng-Yu Tsai, Si Sun, Hongying Zhang, Andrea Local, William Rice, Stephen B. Howell

Cancer Res (2018) 78 (13_Supplement): 4840.

https://doi.org/10.1158/1538-7445.AM2018-4840

Published: 01 July 2018

View article titled, Abstract 4840: APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency

Journal Articles

Abstract 382: Genome-wide location analysis of DNA adducts in vivo

Brian Woo, Christopher Fang, Paolo Abada, Stephen B. Howell, Olivier Harismendy

Cancer Res (2017) 77 (13_Supplement): 382.

https://doi.org/10.1158/1538-7445.AM2017-382

Published: 01 July 2017

View article titled, Abstract 382: Genome-wide location analysis of DNA adducts in vivo

Journal Articles

Abstract 837: Copper efflux transporter-mediated resistance to cisplatin

Ryan A. Mathews, Roohangiz Safaei, Stephen B. Howell

Cancer Res (2012) 72 (8_Supplement): 837.

https://doi.org/10.1158/1538-7445.AM2012-837

Published: 15 April 2012

View article titled, Abstract 837: Copper efflux transporter-mediated resistance to cisplatin

Journal Articles

Abstract 833: The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin

Roohangiz Safaei, Preston L. Adams, Ryan A. Mathews, Stephen B. Howell

Cancer Res (2012) 72 (8_Supplement): 833.

https://doi.org/10.1158/1538-7445.AM2012-833

Published: 15 April 2012

View article titled, Abstract 833: The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin

Journal Articles

Abstract 3627: Targeted delivery of gelonin to claudin-expressing cancer cells and use of activatable cell penetrating peptides to enhance potency

Xinjian Lin, Xiaoqin Yuan, Gerald Manorek, Stephen B. Howell

Cancer Res (2011) 71 (8_Supplement): 3627.

https://doi.org/10.1158/1538-7445.AM2011-3627

Published: 15 April 2011

View article titled, Abstract 3627: Targeted delivery of gelonin to claudin-expressing cancer cells and use of activatable cell penetrating peptides to enhance potency

Journal Articles

Abstract 1554: Claudin 3 (CLDN3) and claudin 4 (CLDN4) control the growth rate of human ovarian cancer cells in vivo

Xinjian Lin, Xiying Shang, Gerald Manorek, Stephen B. Howell

Cancer Res (2011) 71 (8_Supplement): 1554.

https://doi.org/10.1158/1538-7445.AM2011-1554

Published: 15 April 2011

View article titled, Abstract 1554: Claudin 3 (CLDN3) and claudin 4 (CLDN4) control the growth rate of human ovarian cancer cells in vivo

Journal Articles

Abstract 1696: Regulation of sensitivity to the platinum-containing drugs by the sec61 translocon

Paolo B. Abada, Stephen B. Howell

Cancer Res (2011) 71 (8_Supplement): 1696.

https://doi.org/10.1158/1538-7445.AM2011-1696

Published: 15 April 2011

View article titled, Abstract 1696: Regulation of sensitivity to the platinum-containing drugs by the sec61 translocon

Journal Articles

Abstract 5120: A6 peptide binds to CD44 and inhibits migration and metastasis of CD44+ cell lines in in vitro and in vivo studies

Bassam B. Damaj, Francesca Incardonna, Randy Piotrowicz, Stephen B. Howell, Malcolm Finlayson

Cancer Res (2010) 70 (8_Supplement): 5120.

https://doi.org/10.1158/1538-7445.AM10-5120

Published: 15 April 2010

View article titled, Abstract 5120: A6 peptide binds to CD44 and inhibits migration and metastasis of CD44+ cell lines in <em>in vitro</em> and <em>in vivo</em> studies

Journal Articles

The Internalization and Degradation of Human Copper Transporter 1 following Cisplatin Exposure

Alison K. Holzer, Stephen B. Howell

Cancer Res (2006) 66 (22): 10944–10952.

https://doi.org/10.1158/0008-5472.CAN-06-1710

Published: 15 November 2006

View article titled, The Internalization and Degradation of Human Copper Transporter 1 following Cisplatin Exposure

Includes: Supplementary data

Journal Articles

The role of the copper transport protein 1 in the cellular accumulation of cisplatin, oxaliplatin and carboplatin

Alison K. Holzer, Gerald H. Manorek, Stephen B. Howell

Cancer Res (2006) 66 (8_Supplement): 311–312.

Published: 15 April 2006

View article titled, The role of the copper transport protein 1 in the cellular accumulation of cisplatin, oxaliplatin and carboplatin

Journal Articles

hREV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells

Xinjian Lin, Tsuyoshi Okuda, Julie Trang, Stephen B Howell

Cancer Res (2006) 66 (8_Supplement): 879.

Published: 15 April 2006

View article titled, hREV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells

Journal Articles

Differences in the mechanisms of resistance to cisplatin and to JM-118, an active metabolite of satraplatin

Shuichi Kishimoto, Goli Samimi, Gerald H. Manorek, James K. Breaux, Stephen B. Howell

Cancer Res (2006) 66 (8_Supplement): 879–880.

Published: 15 April 2006

View article titled, Differences in the mechanisms of resistance to cisplatin and to JM-118, an active metabolite of satraplatin

Journal Articles

Interaction of cisplatin with the copper efflux transporter ATP7B

Roohangiz Safaei, Barrett J. Larson, Shinji Otani, Michael L. Rasmussen, Nicole B. Chung, Stephen B. Howell

Cancer Res (2006) 66 (8_Supplement): 146–147.

Published: 15 April 2006

View article titled, Interaction of cisplatin with the copper efflux transporter ATP7B

Journal Articles

DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance

Xinjian Lin, Stephen B. Howell

Cancer Res (2006) 66 (8_Supplement): 783–784.

Published: 15 April 2006

View article titled, DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance

NARROW

Abstract 3221: Targeting ARID1A-mutated gastric cancer cells with synthetic lethal approaches

Abstract 3901: Therapeutic targeting of LGR5-positive cancer stem cells

Abstract 4411: A gene set enrichment analysis approach in single-cells along pseudotime trajectories reveals the dynamic activity of oncogenic pathways

Abstract 1323: CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients

Abstract 2096: Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in malignant B cells

Abstract 794: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro

Abstract 4840: APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency

Abstract 382: Genome-wide location analysis of DNA adducts in vivo

Abstract 837: Copper efflux transporter-mediated resistance to cisplatin

Abstract 833: The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin

Abstract 3627: Targeted delivery of gelonin to claudin-expressing cancer cells and use of activatable cell penetrating peptides to enhance potency

Abstract 1554: Claudin 3 (CLDN3) and claudin 4 (CLDN4) control the growth rate of human ovarian cancer cells in vivo

Abstract 1696: Regulation of sensitivity to the platinum-containing drugs by the sec61 translocon

Abstract 5120: A6 peptide binds to CD44 and inhibits migration and metastasis of CD44+ cell lines in in vitro and in vivo studies

The Internalization and Degradation of Human Copper Transporter 1 following Cisplatin Exposure

The role of the copper transport protein 1 in the cellular accumulation of cisplatin, oxaliplatin and carboplatin

hREV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells

Differences in the mechanisms of resistance to cisplatin and to JM-118, an active metabolite of satraplatin

Interaction of cisplatin with the copper efflux transporter ATP7B

DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only